Unique metastasis‐associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma
Autor: | Guixi Zheng, Mingjin Zou, Lutao Du, Jing Hao, Xiaoli Li, Xin Zhang, Yujiao Xie, Xiaoshi Zhang, Jingyi Han, Chuanxin Wang, Weili Duan, Lili Wang, Yinghui Zhao |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Oncology Lung Neoplasms Metastasis 0302 clinical medicine General Medicine Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Gene Expression Regulation Neoplastic Survival Rate medicine.anatomical_structure Lymphatic Metastasis 030220 oncology & carcinogenesis Adenocarcinoma Female RNA Long Noncoding Original Article Pulmonary and Respiratory Medicine medicine.medical_specialty Adenocarcinoma of Lung TNM staging system lcsh:RC254-282 03 medical and health sciences Internal medicine Cancer genome Biomarkers Tumor medicine Humans metastasis Lung cancer Survival analysis Aged Neoplasm Staging Lung Receiver operating characteristic lncRNA signature business.industry Gene Expression Profiling Original Articles prediction lung adenocarcinoma medicine.disease 030104 developmental biology ROC Curve prognosis Neoplasm Recurrence Local business Follow-Up Studies |
Zdroj: | Thoracic Cancer, Vol 11, Iss 3, Pp 728-737 (2020) Thoracic Cancer |
ISSN: | 1759-7714 1759-7706 |
Popis: | Background Local relapses and metastases are primary causes of death in lung cancer patients. In the present study, we aimed to develop a prognostic signature based on metastasis‐associated lncRNAs in patients with lung adenocarcinoma (LUAD). Methods Firstly, the potential metastasis‐associated lncRNAs were identified by analyzing high‐throughput data from The Cancer Genome Atlas (TCGA), and based on which, an lncRNA signature was constructed for prediction of relapse in LUAD patients using Cox proportional hazards regression analysis. Moreover, the prognostic performance of the lncRNA signature was evaluated using Kaplan‐Meier survival analysis, time‐dependent receiver operating characteristic (ROC) curve and Cox analysis, respectively. In addition, the potential metastasis‐associated function of these six lncRNAs was confirmed by lncRNA over‐expression or depletion and in vitro transwell assays in LUAD cells. Results An lncRNA signature consisting of six most important prognostic factors (LINC01819, ZNF649‐AS1, HNF4A‐AS1, FAM222A‐AS1, LINC02323 and LINC00672) was developed. The signature was an independent predictor for patients' relapse‐free survival (RFS), which could provide higher tumor relapse prediction capability compared with the TNM staging system at three years and five years, respectively (P = 0.0209 and P = 0.0468). Furthermore, the combination of this lncRNA signature and TNM stage had better prognostic value than TNM stage alone at three and five years, respectively (P = 0.0006 and P = 0.0096). Additionally, all the lncRNAs of the signature had a regulatory role in the LUAD cell mobility. Conclusions This novel six‐lncRNA signature had considerable prognostic value for prediction of relapse in LUAD patients. Key points Significant findings of the study The unique metastasis‐associated lncRNA signature was related to tumor metastasis and prognosis in LUAD patients. What this study adds This signature had considerable prognostic value for prediction of relapse in LUAD patients. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |